Patents by Inventor Neville Kisalu

Neville Kisalu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240117026
    Abstract: Antibodies and antigen binding fragments that specifically bind to P. falciparum circumsporozoite protein and neutralize P. falciparum are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. The disclosed antibodies, antigen binding fragments, nucleic acids and vectors can be used, for example, to inhibit a P. falciparum infection.
    Type: Application
    Filed: August 2, 2023
    Publication date: April 11, 2024
    Applicants: The U.S.A., as Represented by the Secretary, Department of Health and Human Services, Sanaria Inc.
    Inventors: Robert Seder, Neville Kisalu, Azza Idris, Barbara Flynn, Stephen Hoffman
  • Patent number: 11760794
    Abstract: Antibodies and antigen binding fragments that specifically bind to P. falciparum circumsporozoite protein and neutralize P. falciparum are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. The disclosed antibodies, antigen binding fragments, nucleic acids and vectors can be used, for example, to inhibit a P. falciparum infection.
    Type: Grant
    Filed: April 28, 2021
    Date of Patent: September 19, 2023
    Assignees: The United States of America, as Represented by the Secretary, Department of Health and Human Services, Sanaria Inc.
    Inventors: Robert Seder, Neville Kisalu, Azza Idris, Barbara Flynn, Stephen Hoffman
  • Publication number: 20210253683
    Abstract: Antibodies and antigen binding fragments that specifically bind to P. falciparum circumsporozoite protein and neutralize P. falciparum are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. The disclosed antibodies, antigen binding fragments, nucleic acids and vectors can be used, for example, to inhibit a P. falciparum infection.
    Type: Application
    Filed: April 28, 2021
    Publication date: August 19, 2021
    Applicants: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC, Sanaria Inc.
    Inventors: Robert Seder, Neville Kisalu, Azza Idris, Barbara Flynn, Stephen Hoffman
  • Patent number: 11021535
    Abstract: Antibodies and antigen binding fragments that specifically bind to P. falciparum circumsporozoite protein and neutralize P. falciparum are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. The disclosed antibodies, antigen binding fragments, nucleic acids and vectors can be used, for example, to inhibit a P. falciparum infection.
    Type: Grant
    Filed: February 12, 2018
    Date of Patent: June 1, 2021
    Assignees: The United States of America as represented by the Secretary, Department of Health and Human Services, Sanaria Inc.
    Inventors: Robert Seder, Neville Kisalu, Azza Idris, Barbara Flynn, Stephen Hoffman
  • Publication number: 20190375831
    Abstract: Antibodies and antigen binding fragments that specifically bind to P. falciparum circumsporozoite protein and neutralize P. falciparum are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. The disclosed antibodies, antigen binding fragments, nucleic acids and vectors can be used, for example, to inhibit a P. falciparum infection.
    Type: Application
    Filed: February 12, 2018
    Publication date: December 12, 2019
    Applicants: HUMAN SERVICES, SANARIA INC
    Inventors: Robert Seder, Neville Kisalu, Azza Idris, Barbara Flynn, Stephen Hoffman